

Funding for the CCRN

January 28, 2016



Steering Committee: Dave Gaffney, Henry Kitchener, Sang Young Ryu, Bill Small, Carien Creutzberg, D. Thinh, Anuja Jhingran, Linda Mileskin, A.Covens (IGCS) and Monica Bacon




Figure 2: Estimated most frequent cancer type in 184 countries for both sexes, 2012
 Data are from GLOBOCAN 2012. Data in parentheses are the number of countries in which that cancer is the most common. The map was produced by the International Agency for Research on Cancer (Lyon, France), and reproduced with permission.




Figure 1: Total incidence of, and mortality from, cancer in 2012 worldwide (A), in high and very high HDI countries (B), in medium HDI countries (C), and in low HDI countries (D)
 The top five cancers are shown in the dark grey portion of the pie chart. HDI—Human Development Index.

	Radiotherapy utilisation rate (%)	Mean radiotherapy fractions per course	5-year local control benefit (%)	5-year overall survival benefit (%)
Breast	87	16	15	2
Cervix	71	21	35	20
Colorectal	19	23	5	2
Haematological	48	8	7	4
Head and neck	74	22	34	20
Liver	0	0	0	0
Lung	77	16	9	6
Oesophagus	71	15	5	2
Prostate	58	28	25*	1
Stomach	27	19	2	1
Total	50	18	10	4

Radiotherapy utilisation rate is the number of patients for whom radiotherapy is the treatment of choice according to guidelines and evidence, divided by the number of new cases in one year. Haematological cancers include leukaemia, Hodgkin's lymphoma, non-Hodgkin lymphoma, and multiple myeloma. *5-year biochemical disease-free survival for curative cases only.

Table 1: Radiotherapy utilisation rate, mean fractions, and outcome benefits (absolute proportional) for top ten cancers globally by incidence

CCRN: Significant Issues

- Money (Funding Sources)
 - IGCS (current support)
 - GCIG (current support)
 - Center for Global Health, NIH, USA
 - Gates Foundation
 - Industry (Elekta/Varian/Bebig)
 - Burgeoning market
- Per case reimbursement?
- Accrual
- Ongoing oversight (QA and FU)
- Insurance/Indemnity issues
- Site Selection
- Infrastructure (clinical trials management)

CCRN: Current Support

- Funding Sources (on going)
 - IGCS
 - GCIG
- This meeting supported by:
 - Elekta
 - Varian
 - Bebig
 - Zeria

CCRN: Potential Sources of Support

- Foundation (IGCS)
- CCRN Society (Dues)
- Industry:
 - Elekta
 - Varian
 - Eckert and Ziegler, Bebig
- Pharma
 - Chemo
 - Targeted agents
 - Maintenance agents
 - Immune modulators
- Grants
- Charitable Organizations
- Social Media
- Advocacy Groups

CCRN: Future Support

- Future Sources
 - Center for Global Health, NIH, USA
 - Office of Research in Women's Health, NIH
 - Countries
 - Philanthropy
 - Gates Foundation
 - CCRN Foundation
 - Anuja Jhingran, Liason to IGCS
 - Industry (Elekta/Varian/Bebig/Zeria/others)
 - Burgeoning market